Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

American Bio Medica's oxycodone assay gains US nod:

This article was originally published in Clinica

Executive Summary

American Bio Medica Corporation has received US FDA 510(k) clearance for what it claims is the first on-site, point-of-care test for oxycodone, a synthetic opiate found in commonly abused prescription painkillers, including OxyContin. The Rapid One OXY assay is a urine-based test that can provide results within minutes. It is designed to detect oxycodone at a very low level and does not detect other opiates at this level, says the Kinderhook, New York firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065884

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel